Most bladder tumors have complex genomes characterized by a high mutation burden as
well as frequent copy number alterations and chromosomal rearrangements. Alterations in …

Simple Summary Bladder cancer is the second most common urologic malignancy. Current
standard of care for muscle-invasive bladder cancer is cisplatin-based neoadjuvant …

Because aberrant glycosylation is known to play a role in the progression of melanoma, we
hypothesize that genetic variants of glycosylation pathway genes are associated with the …

Urothelial cancer has long been known as a chemotherapy‐sensitive disease. However,
clinical trial data to date suggest a plateau to the magnitude of benefit from cytotoxic therapy …

The modern treatment of advanced urothelial carcinoma has been built on the foundation of
platinum-containing combination chemotherapy. This therapeutic approach has been in …

Introduction: In cancer, precision medicine, frequently referred to as precision oncology,
implies the use of specific information about a person's tumor to assist diagnosis, guide …

Urinary bladder cancer (UBC) accounts for approximately 430,000 new cases and 165,000
deaths worldwide annually [1], placing as the 9th most common cancer (6th among men and …